Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02082626 · ClinicalTrials.gov registry record · Phase 1
Study of Eribulin in Children With Cancer to Determine Safety
A Phase 1 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT02082626 is a Phase 1 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 3 participants.
The verdict
NCT02082626, a Phase 1 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigators will be monitoring the children on this study for the safety of the treatment and levels of eribulin in the blood after treatment. The investigators will also study the effect of the agent on the cancer.
Interventions
- DRUG Eribulin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-02-01 |
| Est. Completion | 2018-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02082626
The ClinicalTrials.gov registry entry for NCT02082626 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eribulin mesylate is the first listed.
NCT02082626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02082626 about?
NCT02082626 is a clinical study titled "Study of Eribulin in Children With Cancer to Determine Safety". This is a study for children with cancer with no curative treatment options. The investigators will be giving eribulin, a new chemotherapy agent, for the first time to children. This study is designed to determine a safe dose the investigators can give to children in larger studies. The investigator...
What is the current status of trial NCT02082626?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-02-01. Estimated completion is 2018-06.
What interventions are being tested in trial NCT02082626?
The interventions under investigation include: Eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT02082626?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.